CK

Chellam Krishnamoorthy Janakiraman

Active Director Director DIN 10507087
DIN 10507087 First appointment Feb 2024
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Feb 2024
Shareholding value β€’β€’β€’β€’ Premium profile

About Chellam Krishnamoorthy Janakiraman

Data last updated:

Chellam Krishnamoorthy Janakiraman is a Director at Tamyra Congrego Health Care Private Limited (since 2024).

DIN 10507087
Primary Designation Director
First Appointment 14 Feb 2024
Oldest Company Age 2 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director14 Feb 20242024Active

Board colleagues of Chellam Krishnamoorthy Janakiraman

NameDINCompanyDesignation
Sowmya Subramani10507086Tamyra Congrego Health Care Private LimitedManaging Director

Directorship timeline

Open interactive timeline →
Tamyra Congrego Health Care Private Limited
Premium access

Shareholding and investment profile for Chellam Krishnamoorthy Janakiraman

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Chellam Krishnamoorthy Janakiraman

Chellam Krishnamoorthy Janakiraman currently holds 1 directorship: Tamyra Congrego Health Care Private Limited (Director, since 14 Feb 2024).

Chellam Krishnamoorthy Janakiraman was first appointed on 14 Feb 2024 as Director at Tamyra Congrego Health Care Private Limited.

The current boards of Chellam Krishnamoorthy Janakiraman's companies include Sowmya Subramani (Tamyra Congrego Health Care Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available